Subject: PCOS: What It Actually Is, How It’s Managed Now, And The Peptide Mechanisms Worth Watching
From: Derek from Research Radar <[email-masked]>
To: [email-masked]
Date: Tue, 12 May 2026 16:13:59 +0000
List-Id: <derekpruski.substack.com>

View this post on the web at https://derekpruski.substack.com/p/pcos-what-it-actually-is-how-its

One of the most common conditions in women of reproductive age — and one that happens to sit at the intersection of every major mechanism peptide research targets.
Research and educational purposes only. Nothing in this piece is medical advice. PCOS is a medical diagnosis that requires real clinical care — peptides discussed here are research tools, not treatments. If you have PCOS or suspect you do, work with a clinician.
What PCOS Actually Is
Let’s start with the basics.
Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age — affecting roughly 10 to 13 percent of women globally. It’s not a single disease with a single cause. It’s a complex, heterogeneous syndrome where three things tend to show up together:
Irregular or absent ovulation, which leads to irregular periods and fertility issues
Hyperandrogenism — excess androgens, the “male” hormones like testosterone. This is what drives the cosmetic stuff: acne, hirsutism (unwanted hair growth in male-pattern areas), and androgenic hair loss
Polycystic ovarian morphology — multiple small follicles on ultrasound, or elevated anti-Müllerian hormone (AMH)
But the real story is bigger than the ovaries.
PCOS is fundamentally a whole-body metabolic and endocrine condition. Most patients also have insulin resistance, chronic low-grade inflammation, increased risk of type 2 diabetes, obesity, sleep apnea, cardiovascular disease, anxiety, depression, and endometrial cancer.
It’s lifelong. The reproductive symptoms get most of the attention, but the metabolic and psychological consequences extend well past the reproductive years.
What Drives PCOS
There are a few interconnected things going wrong at once. Understanding these matters because every peptide mechanism we’ll discuss later targets one of them.
Genetics. There’s a strong hereditary component. In one study of first-degree relatives, 24 percent of mothers and 32 percent of sisters of PCOS patients also had PCOS. Genome-wide association studies have identified multiple risk genes involved in gonadotropin action, insulin signaling, and androgen biosynthesis. Interestingly, male relatives can show metabolic features of PCOS too — early-onset male-pattern baldness, insulin resistance, type 2 diabetes — suggesting this is a systemic genetic risk, not just ovary-specific.
Epigenetics and environment. The genetic background sets the stage, but environmental factors trigger the actual disorder. Prenatal exposure to elevated androgens, postnatal exposure to endocrine-disrupting chemicals (bisphenol A, certain pesticides, microplastics), poor diet, and sedentary lifestyle all alter gene expression in ways that drive the PCOS phenotype.
Ovarian hyperandrogenism. This is the core issue. About 90 percent of PCOS patients have it. The theca cells in the ovary make too much androgen, which disrupts follicle maturation. Instead of one follicle maturing each cycle and releasing an egg, multiple small follicles arrest at an immature stage. That’s the “polycystic” appearance on ultrasound — they aren’t cysts in the disease sense, they’re stalled follicles.
Insulin resistance and hyperinsulinemia. Insulin resistance is present in a majority of PCOS patients — even in lean ones, which surprises a lot of people. When cells stop responding properly to insulin, the pancreas pumps out more to compensate. That elevated insulin does two damaging things in PCOS:
It directly stimulates the ovaries to make more androgens
It suppresses the liver’s production of sex hormone-binding globulin (SHBG), which means more free testosterone is floating around unbound
This is why fixing insulin resistance is one of the most important targets in PCOS care.
HPO axis dysfunction. The hypothalamic-pituitary-ovarian axis runs the show on the hormonal side. In PCOS, gonadotropin-releasing hormone (GnRH) pulses too fast, which skews luteinizing hormone (LH) higher than follicle-stimulating hormone (FSH). That LH/FSH imbalance further drives ovarian androgen production and impairs ovulation.
Chronic low-grade inflammation. Adipose tissue — especially visceral fat — in PCOS pumps out inflammatory cytokines: TNF-alpha, IL-6, IL-1-beta. The gut microbiome is also altered, with increased intestinal permeability contributing to systemic inflammation. That inflammation worsens insulin resistance, increases ovarian androgen production, and impairs follicle development. It’s a feedback loop.
Mitochondrial dysfunction. This is newer to the conversation but increasingly well-documented. Granulosa cells (the cells supporting the egg) in PCOS show impaired mitochondrial function, elevated reactive oxygen species, and reduced mitochondrial membrane potential. That energy failure in the ovary contributes to follicle arrest and egg quality issues.
How PCOS Is Currently Managed
This is the conventional medicine approach, based on the 2023 international evidence-based guideline. Knowing this matters because it’s the foundation that peptide research is being layered onto.
Lifestyle modification. Always first-line, always non-negotiable. Diet (no single “best” diet — sustainable, individualized matters more than the specific approach), 150-300 minutes of moderate exercise per week plus muscle-strengthening on two days, sleep, stress management. Even modest weight loss (5-10 percent of body weight) can dramatically improve symptoms and restore ovulation in some patients.
Hormonal contraceptives. Combined oral contraceptives are first-line for managing menstrual irregularities and androgen-driven symptoms like acne and hirsutism. They protect the uterine lining from the cancer risk of unopposed estrogen, regulate cycles, and reduce androgens. Formulations with antiandrogenic progestins (drospirenone, dienogest) are preferred when hyperandrogenism is prominent.
Spironolactone. An antiandrogen often added when oral contraceptives alone don’t control hirsutism or acne. Dosing typically 50-200 mg/day. Has fetal toxicity risk, so contraception is required.
Metformin. The old workhorse. It improves insulin sensitivity. The current guideline has cooled on metformin somewhat — it’s not first-line for weight loss or ovulation induction anymore, though it still has a role in adolescents and lean patients with prediabetes or type 2 diabetes. Maximum dose 2000 mg/day, extended-release preferred for tolerability.
GLP-1 receptor agonists. This is where the field is shifting fast. Liraglutide, semaglutide, and exenatide are increasingly used off-label in PCOS. A 2025 meta-analysis showed GLP-1 RAs significantly reduce fasting insulin, post-glucose insulin response, and insulin resistance scores, plus they drive meaningful weight loss. Their mechanism hits multiple PCOS drivers at once — improving insulin sensitivity, reducing inflammation, and indirectly reducing ovarian androgen production. Critical note: pregnancy safety data is lacking, so effective contraception is required for women of reproductive age.
Inositol. Specifically myo-inositol and D-chiro-inositol in research. It’s a second messenger that helps insulin signaling and FSH signaling at the cellular level. The evidence is modest — possible improvement in metabolic measures, but limited effects on ovulation or hirsutism. Low risk of harm, so it shows up frequently as an adjunct.
Letrozole. The first-line ovulation induction drug now (it overtook clomiphene). For PCOS patients trying to conceive who don’t ovulate on their own, letrozole started day 3 of cycle, 2.5 mg titrated up to 7.5 mg as needed.
Bariatric surgery. For PCOS patients with severe obesity who haven’t responded to other interventions. Often produces dramatic improvements in insulin resistance, androgens, and ovulation.
What’s missing from this picture:
There’s no treatment that addresses the root genetic and epigenetic drivers, no targeted way to fix ovarian mitochondrial dysfunction, no clean solution for the chronic inflammation piece, and limited tools for the psychological burden.
This is where peptide research gets interesting.
Why PCOS Is A Peptide Research Target
Here’s why this matters from a peptide research standpoint.
The PCOS phenotype involves several mechanisms that overlap directly with what peptides are known to influence: insulin sensitivity, chronic inflammation, gut barrier integrity, mitochondrial function, HPO axis signaling, and tissue repair. Almost every layer of PCOS pathophysiology has a peptide mechanism that’s been studied for it in some context.
That’s not a claim that any peptide treats PCOS. The point is that the mechanisms PCOS depends on aren’t black boxes — they’re well-mapped pathways, and several peptides have research backing for influencing those exact pathways.
Let’s walk through them.
GLP-1 And Advanced Incretins
This is the most clinically advanced and best-evidenced peptide class for PCOS, so we’ll start here.
GLP-1 receptor agonists (semaglutide, liraglutide, exenatide). Discussed above as part of standard care. The mechanism in PCOS hits three pillars at once: weight loss (reduces adipose-driven inflammation and improves insulin sensitivity systemically), improved insulin sensitivity (lowers compensatory hyperinsulinemia, which is what’s driving ovarian androgen production), and direct anti-inflammatory effects on multiple tissues.
GLP-1/GIP dual agonists (tirzepatide). Tirzepatide adds GIP receptor agonism on top of GLP-1. In PCOS research and metabolic syndrome research more broadly, the addition of GIP signaling produces greater improvements in insulin sensitivity and weight loss compared to GLP-1 alone. The mechanism: GIP signaling enhances insulin sensitivity in adipose tissue and improves the metabolic flexibility of fat cells.
GLP-1/GIP/glucagon triple agonist (retatrutide). Retatrutide adds glucagon receptor agonism — which, somewhat counterintuitively, increases energy expenditure and accelerates fat breakdown for fuel. In a 2025 scoping review, the triple agonist class produced the largest improvements in weight loss and insulin sensitivity in PCOS-relevant research compared to GLP-1 and dual agonists. Retatrutide is still pre-FDA approval but is moving through trials.
What the literature shows specifically for PCOS
Significant reductions in fasting insulin and post-glucose insulin response
Significant improvements in insulin resistance scores (HOMA-IR)
Improvements in dysmenorrhea and ovarian morphology in some studies
Weight loss substantially greater than with metformin
What the literature shows is NOT changed by GLP-1 RAs alone
Total and free testosterone (mostly unchanged in meta-analysis)
DHEA-S, SHBG, free androgen index
Hirsutism scores (modest at best)
The honest interpretation: GLP-1 RAs are powerful tools for the metabolic side of PCOS, but they don’t fully reverse the intrinsic ovarian hyperandrogenism. That confirms PCOS is fundamentally an ovarian disorder exacerbated by metabolic dysfunction — not the other way around. Weight loss alone doesn’t fix everything, but it dramatically improves a lot of it.
BPC-157 And The Gut-Ovary Connection
This is one of the more underrated angles in PCOS peptide research.
The gut microbiome is altered in PCOS. There’s reduced microbial diversity, increased intestinal permeability (”leaky gut”), and this is part of what drives systemic inflammation. That chronic low-grade inflammation worsens insulin resistance and ovarian androgen production. Fix the gut, and you address one of the upstream amplifiers.
BPC-157 (Body Protection Compound). A pentadecapeptide originally derived from gastric juice. The mechanism is multimodal: it promotes gut lining repair, reduces intestinal permeability, modulates the gut-brain axis, supports angiogenesis, and has anti-inflammatory effects. In animal research, BPC-157 has reversed leaky gut syndrome and restored multiple deranged molecular pathways. It’s also been shown to influence dopaminergic signaling, GABA activity, and serotonergic pathways — which is relevant to the psychological symptoms in PCOS (anxiety, depression).
Why this matters for PCOS:
Gut barrier repair reduces endotoxin leakage and systemic inflammation, which improves insulin sensitivity
The gut-brain axis effects are relevant to the mood and anxiety burden in PCOS
The angiogenic and tissue repair properties may support ovarian tissue health
This is not a “BPC-157 treats PCOS” claim. It’s a “the upstream amplifier of inflammation in PCOS partially originates in the gut, and BPC-157 has research evidence for restoring gut barrier function” claim.
KPV (lysine-proline-valine). A C-terminal tripeptide derived from alpha-MSH. Potent anti-inflammatory, immune-modulating, and antimicrobial activity, particularly in the gut and skin. KPV suppresses inflammatory cytokines (TNF-alpha, IL-6) which are the same cytokines elevated in PCOS adipose tissue. Often stacked with BPC-157 for gut-focused protocols. Relevant for the inflammation arm of PCOS.
Kisspeptin And The HPO Axis
This is one of the most directly relevant peptide research areas for PCOS, and it gets very little attention in mainstream peptide communities.
Kisspeptin is a hypothalamic peptide encoded by the KISS1 gene. It’s the master regulator of GnRH neurons — meaning it’s upstream of the entire reproductive hormone cascade. Without kisspeptin signaling, GnRH doesn’t pulse, LH and FSH don’t release properly, and the ovaries don’t function.
In PCOS, kisspeptin signaling is dysregulated. Higher kisspeptin tone contributes to the increased LH pulse frequency that drives ovarian androgen production. But here’s where it gets interesting:
Research published in 2024-2026 has shown that kisspeptin, particularly in local ovarian tissue, plays a different role from its central role — it improves local ovarian insulin resistance and protects mitochondrial function in granulosa cells.
What the recent research shows:
Kisspeptin activates the PI3K/AKT/GLUT4 signaling pathway in ovarian granulosa cells, improving local insulin sensitivity
Kisspeptin reduces reactive oxygen species in granulosa cells and increases mitochondrial membrane potential — protecting energy production in the cells that support egg development
Antagonizing kisspeptin signaling worsens these parameters
This is a fascinating duality: central (hypothalamic) kisspeptin dysregulation drives parts of PCOS pathology, but peripheral (ovarian) kisspeptin appears to be protective. The therapeutic implication is complex — you can’t just turn kisspeptin up or down systemically. But it points to kisspeptin signaling as a major research target, and selective modulators may be a future direction.
For the curious: there are already kisspeptin antagonists being developed for hyperandrogenism and selective agonists being studied for hypogonadism. PCOS is in between, and the research is genuinely active.
Mitochondrial Peptides
Mitochondrial dysfunction in ovarian granulosa cells is one of the more recent additions to the PCOS pathophysiology picture, and it opens up a different category of peptide research.
MOTS-c. A mitochondria-derived 16-amino acid peptide encoded by mitochondrial 12S rRNA. It improves insulin sensitivity, increases mitochondrial efficiency, and modulates metabolic signaling through AMPK activation. MOTS-c has been studied for metabolic syndrome and aging-related metabolic decline. There’s preliminary research suggesting reduced MOTS-c levels in ovarian tissue may be relevant to PCOS pathology, though direct PCOS clinical work is still early.
The connection: PCOS granulosa cells show impaired mitochondrial function. MOTS-c’s mechanism of restoring mitochondrial signaling and improving systemic insulin sensitivity overlaps directly with two major PCOS drivers.
SS-31 (elamipretide). A mitochondrial membrane-stabilizing peptide that binds cardiolipin. SS-31 protects mitochondria from oxidative damage and restores ATP production. While it hasn’t been formally studied in PCOS, the rationale is straightforward — PCOS granulosa cells have damaged mitochondria with reduced membrane potential and elevated ROS, and SS-31 is one of the most direct tools for that exact problem. Research models in oocyte aging (which shares some features with PCOS-related egg quality issues) have shown SS-31 improves oocyte quality.
Urolithin A. A postbiotic mitophagy inducer. UA promotes the clearance of damaged mitochondria and the building of new ones. There’s emerging research suggesting that mitophagy dysfunction in granulosa cells contributes to PCOS, and UA’s mechanism of restoring mitophagy is mechanistically relevant.
None of these have completed PCOS-specific human trials. But mechanistically, the mitochondrial peptide class is one of the more compelling research directions for the ovarian and metabolic dysfunction in PCOS.
Other Peptides Worth Knowing About
A few additional peptides with mechanisms that touch PCOS pathophysiology.
Thymosin Alpha-1. Immune-modulating peptide. PCOS involves chronic low-grade inflammation and skewed immune signaling. While not a direct PCOS therapy, the immune modulation may be relevant to the inflammation arm.
GHK-Cu. Tripeptide-copper complex with anti-inflammatory, antioxidant, and tissue repair effects. Skin-relevant applications connect to the cosmetic burden of PCOS (acne, hyperpigmentation, hair-related issues).
Selank and Semax. Russian-developed cognitive peptides with anxiolytic and BDNF-modulating effects respectively. PCOS has high prevalence of anxiety and depression. These don’t address the underlying PCOS biology but may have relevance for the psychological burden.
Tesofensine. Not a peptide, but worth flagging — it’s a triple monoamine reuptake inhibitor in development for obesity that’s showing strong weight loss data and may be relevant for PCOS patients who don’t tolerate GLP-1 agonists.
The Honest Big Picture
I want to be direct about what this all adds up to.
PCOS is a complex, heterogeneous syndrome with reproductive, metabolic, inflammatory, mitochondrial, and psychological components. No single peptide treats PCOS. The mechanisms peptides influence happen to overlap meaningfully with the mechanisms PCOS depends on — but the actual translation from mechanism to clinical outcome in PCOS specifically is still mostly research-stage.
What we have strong evidence for
GLP-1 receptor agonists genuinely help the metabolic side of PCOS and are now part of mainstream care. The dual and triple incretin agonists (tirzepatide, retatrutide) are likely to outperform GLP-1 alone.
What we have mechanistic plausibility for but limited PCOS-specific clinical data
BPC-157 and KPV for gut-driven inflammation
Kisspeptin modulators for HPO axis dysfunction
MOTS-c, SS-31, and Urolithin A for ovarian mitochondrial dysfunction
Thymosin Alpha-1 for the immune and inflammation piece
What we don’t have
Direct head-to-head PCOS clinical trials of most peptides
Long-term safety data in this specific population
Clear protocols for stacking these with conventional PCOS care
Pregnancy safety data for most peptides (significant issue given fertility goals)
What this means practically: lifestyle modification, the metabolic medications (GLP-1 RAs increasingly central), and hormonal/antiandrogen approaches are the proven foundation. Peptide research is a layer of mechanistic plausibility on top of that foundation, not a replacement for it. Anyone framing peptides as a PCOS “cure” or “primary treatment” is way out over their skis given the current evidence.
The research is genuinely exciting. The clinical translation is still in progress.
Final Thoughts
PCOS is one of the most common conditions in women of reproductive age and one of the most consequential across the lifespan. The mechanisms involved — insulin resistance, hyperandrogenism, chronic inflammation, mitochondrial dysfunction, HPO axis dysregulation, gut barrier issues — happen to be exactly the kinds of mechanisms peptide research is good at addressing.
That’s not a coincidence. PCOS sits at the intersection of metabolic, inflammatory, and endocrine dysfunction. Any therapeutic class that targets those layers will eventually have something to say about PCOS. The fact that incretin peptides are already moving into mainstream PCOS care after starting as diabetes drugs is a strong signal that this pattern will continue.
For anyone reading this who has PCOS or is supporting someone who does: the foundational stuff still matters most. Lifestyle, sleep, exercise, stress management, working with a clinician who actually understands PCOS. Conventional medications when needed. Peptide research is a layer to follow with interest, not a replacement for working the basics.
This is for research and educational purposes only. Nothing in this piece is medical advice. PCOS is a medical diagnosis. Work with a clinician.
If this was useful, share it with someone you know who’s been navigating PCOS and feels like the standard playbook hasn’t fully explained their experience — and let me know in the comments what you’d want me to break down next.
— Derek
References
Cleveland Clinic 2026 PCOS review (primary source)
Sung N, Amir J, Abed Alwahab U, Falcone T. Polycystic ovary syndrome: An update on diagnosis and management. Cleveland Clinic Journal of Medicine. 2026;93(3):176-183. Full text [ https://substack.com/redirect/fdaf1708-28c9-4998-a293-986ccb60eae6?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
2023 international evidence-based guideline
Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767-793. PubMed [ https://substack.com/redirect/6575b4bc-a3cb-4c94-baa8-7de98f8dfb87?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
PCOS pathophysiology (comprehensive review)
Stener-Victorin E, Teede H, Norman RJ, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024;10(1):27. PubMed [ https://substack.com/redirect/babb04a6-9b52-4527-8f9c-606bb46b1cf4?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
GLP-1 receptor agonists in PCOS (2025 meta-analysis)
Lin S, Deng Y, Huang J, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025;15(1):16512. PubMed [ https://substack.com/redirect/3102d403-818f-402c-9ee4-2db5468d1f20?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
GLP-1, dual, and triple agonists in PCOS (2025 scoping review)
The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review. Cureus. 2025. Full text [ https://substack.com/redirect/43449217-f376-4861-a38e-9e1cbd27451b?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
Kisspeptin improving ovarian insulin resistance (2026)
Kisspeptin improves local ovarian insulin resistance in PCOS by modulating the PI3K/AKT/GLUT4 signaling pathway. PLOS One. 2026. Full text [ https://substack.com/redirect/f3f54e39-5471-448f-9371-f7cafe79babd?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
Kisspeptin and PCOS (HPO axis)
Kisspeptin and Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). Full text [ https://substack.com/redirect/bd429ce9-c8a9-438a-8f41-db5802ce1aa5?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
Kisspeptin in granulosa cells (PI3K/AKT/ERK)
Kisspeptin regulates the proliferation and apoptosis of ovary granulosa cells in polycystic ovary syndrome by modulating the PI3K/AKT/ERK signalling pathway. BMC Women’s Health. 2023. Full text [ https://substack.com/redirect/ec9c11f6-afb1-4811-a296-0c92c1e8e57b?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
PCOS oxidative stress and mitochondrial dysfunction
Zeber-Lubecka N, Ciebiera M, Hennig EE. Polycystic ovary syndrome and oxidative stress — from bench to bedside. Int J Mol Sci. 2023;24(18):14126.
Insulin resistance across tissues in PCOS
Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16(1):9.
PCOS gut microbiome
Rizk MG, Thackray VG. Intersection of polycystic ovary syndrome and the gut microbiome. J Endocr Soc. 2020;5(2):bvaa177.
BPC-157 gut-brain axis review
Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Full text [ https://substack.com/redirect/7d9c4b14-536d-4a70-b5be-5c1cae9df7a2?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
MOTS-c in ovarian tissue
Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Full text [ https://substack.com/redirect/b654156d-d27c-4861-abc5-1d7dead4f457?j=eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]
PCOS inflammation (low-grade)
Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011;335(1):30-41.

Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOek0zTWpFeE1Td2lhV0YwSWpveE56YzROakF5TkRRNUxDSmxlSEFpT2pFNE1UQXhNemcwTkRrc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LnhYaEhNbGMwVkw3QVhscE1YdzgxSzkzMHZpQVNMMHpUeFlhNFhGbXQ5ZGciLCJwIjoxOTczNzIxMTEsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc4NjAyNDQ5LCJleHAiOjIwOTQxNzg0NDksImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.sy345H5gq2b48DMuY7WEisy8GgsLWbim42pJJcaK1Eo?